Novartis' Tabrecta is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer with a mutation that leads to MET exon 14 skipping.
CVS Health’s retail/long-term-care segment saw revenues of $22.7 billion for the quarter, driven partially by an 8% uptick in front-store sales and an 8.2% increase in prescription fills.